How to Avoid Covid19 Severe Clinical Evolution?
Paulo Eduardo Ocke Reis1*, Leonardo Roever2, Marcos Cesar Braga Lima3 and Carlos Lenin Jaramillo Cueva4
1Department of Specialized and General Surgery, Fluminense Federal University, Rio de Janeiro, Brazil
2Department of Clinical Research, Federal University of Uberlândia, Brazil
3Especialista em Cardiologia pela Universidade Federal Fluminense, Rio de Janeiro, Brazil
4Especialista em Angiologia e Cirurgia Vascular, Universidad Central del Ecuador, Quito, Ecuador
- *Corresponding Author:
- Paulo Eduardo Ocke Reis
Department of Specialized and General Surgery
Fluminense Federal University, Rio de Janeiro, Brazil
Tell: +55 21 2629-5000
E-mail: [email protected]
Received Date: June 16, 2020; Accepted Date: June 24, 2020; Published Date: July 01, 2020
Citation: Ocke Reis PE, Leonardo R, Marcos Cesar BL, Carlos Lenin JC (2020) How to Avoid Covid19 Severe Clinical Evolution? J Vasc Endovasc Ther. Vol. 5 No. 3: 14.
COVID-19 infection was first described associated with respiratory syndrome and elevated mortality worldwide of a specific group of patients, understanding the cause of coronavirus severe illness complications, remains the cornerstone of efforts to provide better approach and appropriated reduce mortality rate . We proposed a change in the CHADS-VASC score (Table 1) , including one point for Covid-19 at the score, and, thus, indicating the necessity of prophylaxis with anticoagulant therapy . Patients who respond Covid-19 infection with severe clinical evolution has the same comorbidities of CHADS-VASC. It has been shone the pulmonary impairment due to thrombosis [2,3]. Now we propose an algorithm to demonstrate the flow chart that must follow each group of patient’s suspected or carriers of Covid 19, to reduce in hospital mortality (Figure 1).
Figure 1: Algorithm of anticoagulation, in patients with strong suspicion or positive Covid [2-8].
Table 1 Classic CHA2DS2-VASC. Adding one point CHA2DS2-VASC-C 19.2 TIA- Transient Ischemic Attack.
|| History of stroke (TIA)
||Peripheral Vascular Disease
||Suspected or carriers of Covid-19
So in this scenario, seeing beyond, with the modified Score CHADS-VASC-C19 2 and algorithm for prophylaxis of Covid-19 pulmonary vascular thrombosis, step by step, we follow-up each group of patient’s suspected or carriers of Covid 19 [2-8] (Figure 1).
- Huang C, Wang Y, Li X, Ren L, Zhao J, et al. (2020) Clinical features of patients infected with 2019 novel coronavirus in Whuam, China. Lancet 395: 497-506.
- Reis PEO, Lima MC (2020) Can we act preventively to prevent patients with COVID-19 from developing more seriously? J Vasc Bras 19.
- Casarna L, Sonzogni A, Nasr A, Rossi RS, Pellegrinelli A, et al. (2020) Pulmonary post-mortem findings in a large series of COVID-19 cases from Northern Italy. Lancet Infect Dis.
- Klok FA, Barco S, Konstantinides SV (2017) External validation of the VTE-BLEED score for predicting major bleeding in stable anticoagulated patients with venous thromboembolism. Thromb Haemost 117: 1164‐1170.
- Barbar S, Noventa F, Rossetto V, Ferrari A, Brandolin B, et al. (2010) A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score. J Thromb Haemost 8: 2450‐2457.
- Obi AT, Barnes GD, Wakefield TW, Eliason JL, Arndt E, et al. (2020) Practical diagnosis and treatment of suspected venous thromboembolism during COVID-19 pandemic. J Vasc Surg Venous Lymphat Disord 20: 30221-30223.
- Bikdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I, et al. (2020) COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review. J Am Coll Cardiol 75: 2950-2973.
- Wang T, Chen R, Liu C, Liang W, Guan W, et al. (2020) Attention should be paid to venous thromboembolism prophylaxis in the management of COVID-19. Lancet Haematol 7: e362‐e363